Headlines about Glaukos Corporation (NYSE:GKOS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Glaukos Corporation earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 45.7770621038595 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

Shares of Glaukos Corporation (NYSE:GKOS) traded up $0.72 during mid-day trading on Friday, reaching $36.01. The company had a trading volume of 485,889 shares, compared to its average volume of 419,343. The company has a market capitalization of $1.24 billion and a PE ratio of 320.82. Glaukos Corporation has a fifty-two week low of $28.72 and a fifty-two week high of $52.49.

GKOS has been the topic of a number of research analyst reports. Zacks Investment Research lowered Glaukos Corporation from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 12th. BidaskClub lowered Glaukos Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Roth Capital lowered their price target on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Thursday, August 3rd. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $56.00 price target on shares of Glaukos Corporation in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $48.57.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Glaukos Corporation (GKOS) Stock Price” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/04/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-glaukos-corporation-gkos-stock-price.html.

In other news, Director Orbimed Advisors Llc sold 325,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $37.93, for a total transaction of $12,327,250.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Thomas William Burns sold 1,212 shares of the firm’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $41.25, for a total transaction of $49,995.00. The disclosure for this sale can be found here. Insiders have sold a total of 980,200 shares of company stock worth $37,900,263 in the last quarter. Corporate insiders own 16.40% of the company’s stock.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Insider Buying and Selling by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.